No pills, more skills: The adverse effect of hormonal contraceptive use on exposure therapy benefit.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
12 2019
Historique:
received: 22 07 2019
revised: 26 09 2019
accepted: 27 09 2019
pubmed: 8 10 2019
medline: 15 9 2020
entrez: 8 10 2019
Statut: ppublish

Résumé

Hormonal contraceptive use can aggravate existing symptoms of anxiety and depression and influence the response to pharmacologic treatment. The impact of hormonal contraceptive use on non-pharmacological treatment efficacy in anxiety disorders is less well explored. Oral contraceptives, which suppress endogenous sex hormone secretion, can alter fear extinction learning. Fear extinction is considered the laboratory proxy of exposure therapy in anxiety disorders. This study set out to examine whether oral contraceptive use is related to exposure-based treatment response in specific phobia. We recruited spider-phobic women (n = 28) using oral contraceptives (OC) and free-cycling women (n =26, No-OC). All participants were subjected to an identical in-vivo exposure. Exposure-based symptom improvement was assessed with several behavioral and subjective indices at pre-treatment, post-treatment and six-weeks follow-up. No-OC women showed higher pre-exposure fear levels on the FSQ and SPQ. OC women showed slightly less pronounced exposure benefit compared to their free-cycling counterparts (No-OC woman) as reflected by lower levels of fear reduction from pre-treatment to follow-up on the subjective level. After correction for multiple testing, OC and No-OC women showed differences in self-report measures (SPQ, FAS and SBQ) from pre- to follow-up treatment but not from pre-to post-treatment. These findings implicate that oral contraceptive use can account for differential exposure-based fear symptom improvement. Our study highlights the importance of monitoring and managing hormonal contraceptives use in the context of non-pharmacological exposure-based interventions.

Identifiants

pubmed: 31590077
pii: S0022-3956(19)30841-6
doi: 10.1016/j.jpsychires.2019.09.016
pii:
doi:

Substances chimiques

Contraceptives, Oral, Hormonal 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

95-101

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Friederike Raeder (F)

Ruhr University, Faculty of Psychology, Mental Health Research and Treatment Center, Bochum, Germany.

Franziska Heidemann (F)

Ruhr University, Faculty of Psychology, Mental Health Research and Treatment Center, Bochum, Germany.

Manfred Schedlowski (M)

Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Jürgen Margraf (J)

Ruhr University, Faculty of Psychology, Mental Health Research and Treatment Center, Bochum, Germany.

Armin Zlomuzica (A)

Ruhr University, Faculty of Psychology, Mental Health Research and Treatment Center, Bochum, Germany. Electronic address: armin.zlomuzica@rub.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH